Sionna Therapeutics to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Sionna Therapeutics (NASDAQ:SION) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $58.00 price target on the stock.
Assessing Sionna Therapeutics (SION) Valuation After Recent Share Price Swings And Premium P/B Multiple [Yahoo! Finance]
Sionna Therapeutics (NASDAQ:SION) had its price target raised by analysts at BTIG Research from $50.00 to $58.00. They now have a "buy" rating on the stock.
Sionna Therapeutics (NASDAQ:SION) had its "strong-buy" rating reaffirmed by analysts at Raymond James Financial, Inc..